- cafead Apr 05, 2022 at 11:12: AM
via With tax day right around the corner in the U.S., Merck & Co. is the latest Big Pharma to find itself in the crosshairs of a congressional tax probe.
Sen. Ron Wyden, the chairman of the Senate Finance Committee, on Monday wrote to Merck CEO Robert Davis asking how the company managed to pay a tax rate of just 11% last year. As Sen. Wyden notes, Merck's "legal domicile" is in the U.S., and that's where most of the company's R&D activities take place.
article source
Sen. Ron Wyden, the chairman of the Senate Finance Committee, on Monday wrote to Merck CEO Robert Davis asking how the company managed to pay a tax rate of just 11% last year. As Sen. Wyden notes, Merck's "legal domicile" is in the U.S., and that's where most of the company's R&D activities take place.
article source